[
  {
    "ts": "2026-02-23T17:09:17+00:00",
    "headline": "Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY?",
    "summary": "Incyte Corporation recently reported past fourth-quarter 2025 results showing revenue of US$1,506.84 million and net income of US$299.28 million, alongside full-year 2025 revenue of US$5.14 billion and net income of US$1,286.65 million, and issued 2026 total net product revenue guidance of US$4.77 billion to US$4.94 billion. The sharp improvement in earnings and profitability, coupled with guidance that points to substantial product revenue, underscores how Incyte’s expanding oncology and...",
    "url": "https://finance.yahoo.com/news/does-incyte-2025-beat-2026-170917969.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "30748bcf-8fac-3374-8ba7-23fb6667177c",
      "content": {
        "id": "30748bcf-8fac-3374-8ba7-23fb6667177c",
        "contentType": "STORY",
        "title": "Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY?",
        "description": "",
        "summary": "Incyte Corporation recently reported past fourth-quarter 2025 results showing revenue of US$1,506.84 million and net income of US$299.28 million, alongside full-year 2025 revenue of US$5.14 billion and net income of US$1,286.65 million, and issued 2026 total net product revenue guidance of US$4.77 billion to US$4.94 billion. The sharp improvement in earnings and profitability, coupled with guidance that points to substantial product revenue, underscores how Incyte’s expanding oncology and...",
        "pubDate": "2026-02-23T17:09:17Z",
        "displayTime": "2026-02-23T17:09:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-incyte-2025-beat-2026-170917969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-incyte-2025-beat-2026-170917969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:57:30+00:00",
    "headline": "Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet",
    "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.",
    "url": "https://www.fool.com/coverage/filings/2026/02/23/baker-bros-loads-up-kymr-with-2-million-shares/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7f6cbd96-eb8f-3ca2-8d0b-8156b06ad1c6",
      "content": {
        "id": "7f6cbd96-eb8f-3ca2-8d0b-8156b06ad1c6",
        "contentType": "STORY",
        "title": "Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet",
        "description": "",
        "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.",
        "pubDate": "2026-02-23T18:57:30Z",
        "displayTime": "2026-02-23T18:57:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aTdlCNCN.XlGUNVNqBzqyQ--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4YpTbzYpiEyrBvOAscyuKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/23/baker-bros-loads-up-kymr-with-2-million-shares/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kymera-stock-130-135-million-185730014.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "INSM"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "ACAD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:49:01+00:00",
    "headline": "Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year",
    "summary": "Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.",
    "url": "https://www.fool.com/coverage/filings/2026/02/23/investor-buys-up-usd81-million-in-praxis-stock-as-shares-soar-over-300-in-one-year/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "855d7ef4-b4e9-3314-817b-0d1bd41640da",
      "content": {
        "id": "855d7ef4-b4e9-3314-817b-0d1bd41640da",
        "contentType": "STORY",
        "title": "Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year",
        "description": "",
        "summary": "Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.",
        "pubDate": "2026-02-23T18:49:01Z",
        "displayTime": "2026-02-23T18:49:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4fca09be06e91fc5e2cb8f5a231f5022",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oqttf5tlzXq40CCw5vhh.w--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4fca09be06e91fc5e2cb8f5a231f5022.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C4P85NVT5wnz_pX8utObMg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4fca09be06e91fc5e2cb8f5a231f5022.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/23/investor-buys-up-usd81-million-in-praxis-stock-as-shares-soar-over-300-in-one-year/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investor-buys-81-million-praxis-184901311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PRAX"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "INSM"
            },
            {
              "symbol": "ACAD"
            },
            {
              "symbol": "MDGL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:40:26+00:00",
    "headline": "Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy",
    "summary": "Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions.",
    "url": "https://www.fool.com/coverage/filings/2026/02/23/kodiak-sciences-stock-up-480-as-one-fund-discloses-usd53-million-buy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f51591ad-e47c-36b7-809d-e83ad236583a",
      "content": {
        "id": "f51591ad-e47c-36b7-809d-e83ad236583a",
        "contentType": "STORY",
        "title": "Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy",
        "description": "",
        "summary": "Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions.",
        "pubDate": "2026-02-23T18:40:26Z",
        "displayTime": "2026-02-23T18:40:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/55916c6de45811c79dd776522bf246b8",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M9ZQxF5B3l1nPszK_E_Tgg--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/55916c6de45811c79dd776522bf246b8.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hh0EjtDutHxedAk7m9wnyg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/55916c6de45811c79dd776522bf246b8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/23/kodiak-sciences-stock-up-480-as-one-fund-discloses-usd53-million-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kodiak-sciences-stock-480-one-184026720.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KOD"
            },
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "INSM"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "ACAD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:26:56+00:00",
    "headline": "This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%",
    "summary": "GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.",
    "url": "https://www.fool.com/coverage/filings/2026/02/23/this-fund-bet-nearly-usd40-million-on-grail-last-quarter-the-stock-just-plunged-over-50/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c19e20c9-7d5b-38d7-be37-3811827b0f07",
      "content": {
        "id": "c19e20c9-7d5b-38d7-be37-3811827b0f07",
        "contentType": "STORY",
        "title": "This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%",
        "description": "",
        "summary": "GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.",
        "pubDate": "2026-02-23T18:26:56Z",
        "displayTime": "2026-02-23T18:26:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c8fdbaad0052ddeb52dc04acadae8795",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2azMnzFtuMPv8RQB8l4a_Q--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c8fdbaad0052ddeb52dc04acadae8795.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fsodDr1.ouENolCZLSiAtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c8fdbaad0052ddeb52dc04acadae8795.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/23/this-fund-bet-nearly-usd40-million-on-grail-last-quarter-the-stock-just-plunged-over-50/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fund-bet-nearly-40-million-182656455.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "INSM"
            },
            {
              "symbol": "ACAD"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]